In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
ESC TV – Guidelines

News and opinions on the latest ESC Clinical Practice Guidelines.

Watch now

Cancer treatments & cardiovascular toxicity 2016 (Position Paper)

This document reviews the different steps in cardiovascular monitoring and decision-making before, during and after anticancer treatment with potential cardiovascular side-effects. This document aims to assist professionals involved in the treatment of patients with cancer and survivors by providing an expert consensus reading current standards of care for these individuals.

Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease

Guidelines version available to download

  • Published in: 2016
    Reference Eur Heart J (2016) 37 (36): 2768-2801- doi:10.1093/eurheartj/ehw211
  • Published in: 2016
  • Published in: 2016
    Reference Online document
  • Published in: 2017

Table of contents: Full Text (ESC Clinical Practice Guidelines)

Table of Contents

Abbreviations and acronyms



Cardiovascular complications of anticancer therapy: pathophysiology and management

  • Myocardial dysfunction and heart failure
  • Coronary artery disease
  • Valvular disease
  • Arrhythmias
  • Arterial hypertension
  • Thromboembolic disease
  • Peripheral vascular disease and stroke
  • Pulmonary hypertension
  • Other cardiovascular complications of anticancer treatment
  • Cardiovascular complications of anticancer treatment in special populations

Strategies for prevention and attenuation of cardiovascular complications of anticancer therapy

  • Treatment options to prevent or recover from cancer therapy-induced myocardial dysfunction
  • Prevention of thromboembolic events
  • Strategies for attenuation of complications related to use of specific agents

Long-term surveillance programmes for cancer survivors

  • Myocardial dysfunction
  • Vascular disease
  • Valvular disease

Future perspectives and research directions